ADXS Advaxis Inc.

-0.02  -6%
Previous Close 0.39
Open 0.38
Price To Book 1.04
Market Cap 25330150
Shares 69,703,219
Volume 437,338
Short Ratio
Av. Daily Volume 965,775

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Updated data due 1Q 2019.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Phase 3 partial clinical hold announced January 23, 2019. No new enrolments permitted until hold released.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 tolerability data due 1H 2019.
Non-small cell lung cancer (NSCLC)
Phase 1/2 commencement of enrolment announced February 14, 2019 with initial data 1H 2019.
Non-small cell lung cancer (NSCLC)

Latest News

  1. Advaxis (ADXS) Upgraded to Buy: Here's What You Should Know
  2. Advaxis Announces Enrollment of the First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer
  3. How Financially Strong Is Advaxis, Inc. (NASDAQ:ADXS)?
  4. Advaxis Presents an Overview of its Lm Platform and Neoantigen-Directed Programs at the Immuno-Oncology 360° Conference
  5. Edited Transcript of ADXS earnings conference call or presentation 15-Jan-19 4:00pm GMT
  6. New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis — Consolidated Revenues, Company Growth, and Expectations for 2019
  7. Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference
  8. Data Highlighting Potential Benefits of Lm Platform Presented at 2019 Keystone Symposia Conference on Cancer Vaccines
  9. Immunomodulation Bolsters Scientific Advisory Board with Appointments of Robert G. Petit, Ph.D. and Rex Chin-Wei Yung, M.D., F.C.C.P.
  10. The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial
  11. Advaxis’ Phase 3 AIM2CERV Study Placed on Partial Clinical Hold by FDA Related to CMC Requests
  12. The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
  13. Advaxis (ADXS) Reports Q4 Loss, Tops Revenue Estimates
  14. Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update
  15. Advaxis to Host Business Update Conference Call on January 15, 2019
  16. Will Advaxis (ADXS) Report Negative Earnings Next Week? What You Should Know
  17. Could Advaxis, Inc.’s (NASDAQ:ADXS) Investor Composition Influence The Stock Price?
  18. Advaxis to Present at LD Micro Main Event
  19. Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting
  20. Advaxis Provides Update on Clinical Pipeline